Option chain shows key data for Emmaus Life Sciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Emmaus Life Sciences.

Emmaus Life Sciences (OTC:EMMA) Stock, Option Chain

Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies predominantly for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering.

Penny,Stock,Investments,Taking,Off,Concept

Penny Stocks

Markets

EMMA

ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying

Long Ideas

News

Insider Trades

Pre-Market Outlook

Trading Ideas

ETST

The Dow Jones index closed higher by around 0.1% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Great Elm Group And 2 Other Stocks Under $2 Insiders Are Buying

AWRE

STRR

US crude oil futures traded sharply higher this morning on Friday. Investors, meanwhile, focused on some notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Star Equity Holdings And 2 Other Stocks Under $2 Insiders Are Aggressively Buying

EMMAUS LIFE SCIENCES INC by Emmaus Life Sciences, Inc.

Emmaus Life Sciences Inc

Small Cap

Press Releases

Emmaus Life Sciences Reports Delayed Filing of Annual Report

Earnings

Emmaus Life Sciences Reports 2023 Financial Results

Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program

Emmaus Life Sciences Announces Willis C. Lee as Chief Executive Officer

Emmaus Life Sciences Reports Quarterly Financial Results

Emmaus Life Sciences Reports Improved Quarterly Financial Results

Contracts

Emmaus Life Science Reports Grant of Endari Market Exclusivity In Kingdom of Saudi Arabia

Emmaus Life Sciences

Comments

Emmaus Life Sciences

Emmaus Life Sciences (EMMA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga